Genfit stock
GNFT.PAPARGenfit S.A., HealthcareISIN FR0004163111
44Score 44 out of 100, Weak
Price and trend
80 / 100
Price history
+186% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 6.2% above it.
Since November 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 66).
The price is 26% below its 52-week high. Largest decline in 20 years: 96% (February 2015 to December 2021).
Chart figures for advanced users
- SMA 50$11.45
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.31
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)66
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.12
- The lowest closing price of the last twelve months.
- Resistance$16.24
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Genfit S.A. belongs to the Biotechnology industry (France) and, with a market value of $601.03M, is number 231 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $72.51M (down 2.3% year on year) and a loss of $95.26M.
- MEQIRI Score 44 out of 100 (Weak): rank 471 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 143.5% a year since 2020, Biotechnology median 19.4%.Growth 70
Weaknesses
- DilutionShare count up 28% since 2020.Capital allocation 18
- Loss-makingLoss of $113.17M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 66% a year over the last 12 months.Stability 33
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 17.5% on the twelve months before. Revenue has grown solidly since 2006, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 22%, operating −90%, net −131%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 8 Apr 2027in 146 days
- Last reported
- 28 Sep 2026EPS reported −$0.23 (expected −$0.18)below expectations
Analyst estimates
- Earnings per share
- $0.15+2,010.1%
- Revenue
- $91.02M+6.8%
- Earnings per share
- $0.95+404.9%
- Revenue
- $119.37M+40.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Genfit
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 44
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Cullinan TherapeuticsCGEM $626.26M34
- Wave Life SciencesWVE $623.24M38
- Monopar TherapeuticsMNPR $622.21M42
- Sana BiotechnologySANA $602.27M29
- Capricor TherapeuticsCAPR $593.02M33
- Entera BioENTX $560.72M44
- Adlai NortyeANL $558.4M36
- ValnevaVLA.PA $554.46M29
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 2 May 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.